Organon
Organon & Co., a global healthcare company headquartered in the United States, focuses on women's health, biosimilars, and other critical therapeutic areas. Founded in 2021, Organon emerged as a spin-off from Merck & Co., marking a significant milestone in the pharmaceutical industry. The company is dedicated to addressing unmet medical needs through innovative products and services, particularly in reproductive health and chronic conditions.
With a robust portfolio that includes contraceptives, hormone therapies, and biosimilars, Organon distinguishes itself by prioritising women's health and empowering patients. The company has quickly established a strong market position, recognised for its commitment to improving health outcomes and enhancing access to essential medications. As it continues to expand its global footprint, Organon remains focused on delivering impactful solutions that resonate with healthcare providers and patients alike.
-15 vs industry average
Organon’s score of 23 is lower than 37% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Organon?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2025
Reported emissions
Scope 3 accounts for ••• of total emissions.
Organon's reported carbon emissions
In 2022, Organon reported total carbon emissions of approximately 1,059,000,000 kg CO2e, encompassing Scope 1, Scope 2, and Scope 3 emissions. The breakdown includes Scope 1 emissions of 6,580,000 kg CO2e, Scope 2 emissions of 30,784,000 kg CO2e, and significant Scope 3 emissions amounting to 1,029,000,000 kg CO2e. Organon has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 greenhouse gas emissions by more than 25% from 2020 levels by the year 2025. This target reflects the company's proactive approach to addressing its carbon footprint and aligns with industry standards for climate action. The emissions data is sourced directly from Organon & Co., with no cascading from a parent organisation. The company is committed to transparency in its environmental impact and continues to monitor and report its emissions as part of its sustainability initiatives.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Organon’s Climate Goals (2030 & 2050)
2 goals2025
25% reduction in Scope 1
we aim to reduce our Scope 1 and 2 GHG emissions by more than 25% from 2020 levels.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 2 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
2 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Organon
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project